• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antidepressants Don’t Raise Dementia Risk, With One Exception

Antidepressants Don’t Raise Dementia Risk, With One Exception

May 8, 2019
Rehan Aziz, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rehan Aziz, MD. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Heath L et al, JAGS 2018;66(10):1948–1955

Type of study: Prospective cohort study

Depression is a risk factor for dementia, but can antidepressants change that risk? Some, like paroxetine (Paxil), have anticholinergic properties that can impair cognition. This study looked at what that means for the risk of dementia.

This was a prospective cohort study of 3,049 patients without dementia in the Kaiser Permanente Washington system. All subjects were over 65 (average age 75); the majority were white, and 60% were female. Patients were screened for dementia at baseline and evaluated with the Cognitive Abilities Screening Instrument every 2 years. Average follow-up was 8 years. The outcome—a diagnosis of ­dementia—was assessed by clinical evaluation, objective testing, and multidisciplinary conferences.

Half of the patients filled an antidepressant prescription, as assessed by the system’s pharmacy database. By the end of the study, 25% had developed dementia, the majority of whom (85%) were thought to have Alzheimer’s disease. Non-paroxetine SSRIs and tricyclics did not increase the dementia risk. The serotonin antagonist and reuptake inhibitors (trazodone and nefazodone) were associated with a lower risk of dementia, but this may have been due to the tendency to prescribe trazodone to non-depressed patients with insomnia.

The big story here, though, was paroxetine. It was associated with a higher risk of dementia in a non-dose-dependent manner (hazard ratio 1.7–2.1). This association held up after controlling for other factors such as anxiety, insomnia, and cerebrovascular disease.

This is not the first study to look at the association between antidepressants and dementia, but it is one of only 2 studies that has controlled for depression, which itself is a risk factor. The other, a case-control study comparing anticholinergic drugs in 40,000 patients, also implicated paroxetine, as well as the tricyclic amitriptyline (Richardson K et al, BMJ 2018;361:k1315).

TCPR’s Take
Anticholinergic antidepressants can cause a number of problems in the elderly, including urinary retention, constipation, temperature imbalance, confusion, blurry vision, and tachycardia. Dementia may be added to that list, at least with paroxetine and possibly the tricyclics. However, more data are needed. As for other antidepressants, it was refreshing to learn they didn’t increase dementia risk.
General Psychiatry
KEYWORDS research_updates
Rehan Aziz, MD.

Mood Stabilizers for Bipolar Disorder in Older Adults: Special Considerations

More from this author
www.thecarlatreport.com
Issue Date: May 8, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Depression, TCPR, May 2019
Antidepressants Don’t Raise Dementia Risk, With One Exception
Ask the Editor: Can Antipsychotics Enhance Cognition?
An Antidepressant Diet
The Antidepressant Diet: Cookbook and Patient Handouts
Treating Sexual Side Effects
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.